Cargando…
Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
BACKGROUND: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up. METHODS: This is a single ins...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261409/ https://www.ncbi.nlm.nih.gov/pubmed/34295729 http://dx.doi.org/10.21037/tau-20-955 |
_version_ | 1783719006157406208 |
---|---|
author | El-Taji, Omar Al-Mitwalli, Abdullah Malik, Farhan Agarwal, Samita Gogbashian, Andrew Hughes, Rob Vasdev, Nikhil Sharma, Anand |
author_facet | El-Taji, Omar Al-Mitwalli, Abdullah Malik, Farhan Agarwal, Samita Gogbashian, Andrew Hughes, Rob Vasdev, Nikhil Sharma, Anand |
author_sort | El-Taji, Omar |
collection | PubMed |
description | BACKGROUND: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up. METHODS: This is a single institutional, retrospective cohort study of patients with a histological diagnosis of a secondary bladder neoplasm from January 2007 to December 2017 (n=40). Prognostic variables examined included age at diagnosis, histology, disease free survival and treatment. Kaplan-Meier analysis was used to calculate survival. We used multiple regression analysis to identify the most significant treatments for each population group in terms of their survival. RESULTS: Twenty-one patients were male (53%) with a median age of 68 and 19 were female (47%) with a median age of 64. The most common secondary neoplasms and their median survival were prostate [12 patients (30%), 446 days], colorectal [9 patients (23%), 403 days], ovarian [5 patients (13%), 369 days], cervical [4 patients (10%), 148 days], breast [3 patients (8%), 241 days], lymphoma [3 patients (8%), 145 days], gastric [2 patients (5%), 66 days], and renal [2 patients (5%), 854 days]. Those receiving treatment following a secondary diagnosis demonstrated statistical significance in survival for colorectal (surgery P=0.013), prostate (radiotherapy P=0.0012 and hormonal therapy P=0.004) and ovarian cancer (chemotherapy P=0.00002). CONCLUSIONS: Prognosis and treatment depends upon the primary neoplasm. There is some survival benefit in well selected patients receiving treatment following a diagnosis of a bladder secondary. |
format | Online Article Text |
id | pubmed-8261409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-82614092021-07-21 Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes El-Taji, Omar Al-Mitwalli, Abdullah Malik, Farhan Agarwal, Samita Gogbashian, Andrew Hughes, Rob Vasdev, Nikhil Sharma, Anand Transl Androl Urol Original Article BACKGROUND: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up. METHODS: This is a single institutional, retrospective cohort study of patients with a histological diagnosis of a secondary bladder neoplasm from January 2007 to December 2017 (n=40). Prognostic variables examined included age at diagnosis, histology, disease free survival and treatment. Kaplan-Meier analysis was used to calculate survival. We used multiple regression analysis to identify the most significant treatments for each population group in terms of their survival. RESULTS: Twenty-one patients were male (53%) with a median age of 68 and 19 were female (47%) with a median age of 64. The most common secondary neoplasms and their median survival were prostate [12 patients (30%), 446 days], colorectal [9 patients (23%), 403 days], ovarian [5 patients (13%), 369 days], cervical [4 patients (10%), 148 days], breast [3 patients (8%), 241 days], lymphoma [3 patients (8%), 145 days], gastric [2 patients (5%), 66 days], and renal [2 patients (5%), 854 days]. Those receiving treatment following a secondary diagnosis demonstrated statistical significance in survival for colorectal (surgery P=0.013), prostate (radiotherapy P=0.0012 and hormonal therapy P=0.004) and ovarian cancer (chemotherapy P=0.00002). CONCLUSIONS: Prognosis and treatment depends upon the primary neoplasm. There is some survival benefit in well selected patients receiving treatment following a diagnosis of a bladder secondary. AME Publishing Company 2021-06 /pmc/articles/PMC8261409/ /pubmed/34295729 http://dx.doi.org/10.21037/tau-20-955 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article El-Taji, Omar Al-Mitwalli, Abdullah Malik, Farhan Agarwal, Samita Gogbashian, Andrew Hughes, Rob Vasdev, Nikhil Sharma, Anand Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
title | Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
title_full | Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
title_fullStr | Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
title_full_unstemmed | Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
title_short | Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
title_sort | secondary neoplasms of the urinary bladder-clinical management and oncological outcomes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261409/ https://www.ncbi.nlm.nih.gov/pubmed/34295729 http://dx.doi.org/10.21037/tau-20-955 |
work_keys_str_mv | AT eltajiomar secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT almitwalliabdullah secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT malikfarhan secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT agarwalsamita secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT gogbashianandrew secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT hughesrob secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT vasdevnikhil secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes AT sharmaanand secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes |